Inebilizumab Earns FDA Breakthrough Designation for IgG4-RD; New Data at ACR 2024
Hansoh Pharmaceutical Group Co., Ltd. (03692.HK) announced that the U.S. FDA has granted Breakthrough Therapy Designation (BTD) to Inebilizumab for the treatment of Immunoglobulin G4-related disease (IgG4-RD). This designation follows…
Bylvay® Data Shows Continued Improvement in Itch and Bile Acid Levels in PFIC and ALGS
Ipsen (Euronext: IPN; ADR: IPSEY) presented new data at the American Association for the Study of Liver Diseases (AASLD) from two Phase III open-label extension studies, evaluating the long-term efficacy…
Hospital Data Reveals New Insights on Maternal and Newborn Health in Nigeria
A team of Nigerian researchers and clinicians, led by Aminu Kano Teaching Hospital, has made significant progress in understanding maternal and newborn health through a groundbreaking data initiative. In collaboration…
Baku COP29 Strengthens Health-Climate Initiatives with Launch of New Coalition
The United Nations Climate Change Conference (COP29) in Baku achieved a pivotal advancement in aligning health and climate agendas. Building on commitments from previous COPs, this year’s conference emphasized tangible…
Halozyme Shares Update on Potential Merger Proposal with Evotec
Halozyme Therapeutics, Inc. (NASDAQ: HALO) has provided an update regarding its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) for €11.00 per share in cash, valuing the transaction at approximately…
BridgeBio Publishes Phase 2 Infigratinib Study for Achondroplasia in NEJM
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a biopharmaceutical company focused on genetic diseases, has announced positive 18-month results from the Phase 2 PROPEL 2 trial evaluating infigratinib as a treatment for…
Extended Data Confirms Acoramidis Sustains Cardiovascular Benefits, Reduces ACM at 36 Months
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a biopharmaceutical company focused on genetic diseases, has announced positive interim results from the ATTRibute-CM open-label extension (OLE) study of acoramidis, presented at the American…
Alnylam Reports Phase 1 Data: Nucresiran Shows Rapid, Sustained TTR Knockdown After One Dose
Alnylam Pharmaceuticals (Nasdaq: ALNY) presented encouraging Phase 1 results for nucresiran (formerly ALN-TTRsc04), a next-generation RNAi therapeutic for transthyretin (ATTR) amyloidosis, at the American Heart Association Scientific Sessions 2024 in…
WHO and Partners Unite in Efforts to Eliminate Cervical Cancer
As world leaders gather in Rio de Janeiro, Brazil, for the G20 Summit this weekend, the city’s iconic Christ the Redeemer statue will be bathed in teal light in a…
Merck Receives Positive EU CHMP Opinion for KEYTRUDA
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM) Merck (NYSE: MRK), known as MSD outside…
Greywolf Appoints Darlene Deptula-Hicks as Chief Financial Officer
Greywolf Therapeutics, a clinical-stage biotech company advancing novel antigen modulation technology that controls T cells to guide the immune system, has appointed Darlene Deptula-Hicks as Chief Financial Officer. An accomplished…
Equillium reports Q3 2024 financial results and shares corporate and clinical updates
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel…